Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tetryzoline, also known as tetrahydrozoline, is a sympathomimetic amine and selective alpha-adrenoceptor agonist used primarily as an ocular and nasal decongestant. It acts by stimulating alpha‑1 adrenergic receptors in the arterioles of the conjunctiva and nasal mucosa, leading to vasoconstriction. This mechanism reduces redness and swelling in the eyes caused by minor irritants (such as dust, smoke, or pollen) and relieves nasal congestion. Tetryzoline is available over-the-counter in eye drops (notably under brands like Visine) for temporary relief of eye redness and irritation, as well as in some nasal sprays (e.g., Tyzine). It may be combined with other agents such as lubricants or antihistamines for enhanced effect. The drug can cross the blood-brain barrier; systemic absorption may cause central nervous system effects including sedation at high doses[1][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tetryzoline.